Highlight of potential impact of new viral genotypes of SARS-CoV-2 on vaccines and anti-viral therapeutics

Ghorbani, Abozar; Samarfard, Samira; Jajarmi, Maziar; Bagheri, Mahboube; Karbanowicz, Thomas P.; Afsharifar, Alireza; Eskandari, Mohammad Hadi; Niazi‎, Ali; Izadpanah, K.

doi:10.1016/j.genrep.2022.101537

Cited by 3 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) the causal agent of a zoonotic disease called COVID-19 infected more than 422 M people including 5.8 M deaths as of February 2022 [ 1 , 2 ]. Despite the widespread vaccination against the disease, the global number of new cases increased sharply due to the attenuation of the vaccine-induced immunity over time and the emergence of new variants [ 1 , [3] , [4] , [5] ]. Although the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) have infected many people in 2012 and 2003, respectively, the SARS-CoV-2 is the deadliest coronavirus to have ever emerged in the human population [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs

Eskandarzade¹,

Ghorbani²,

Samarfard³

et al. 2022

Computers in Biology and Medicine

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs

Eskandarzade¹,

Ghorbani²,

Samarfard³

et al. 2022

Computers in Biology and Medicine

Self Cite

View full text Add to dashboard Cite

“…ORF1ab:H5614Y (NSP13) and S:L141F, which have been predicted to interfere with antiviral drug binding ( Ameen et al. 2021 ; Ghorbani et al. 2022 ), also emerged after the plasma administration.…”

Section: Discussionmentioning

confidence: 99%

VIPERA: Viral Intra-Patient Evolution Reporting and Analysis

Álvarez-Herrera,

Sevilla,

Ruiz-Rodriguez

et al. 2024

Virus Evolution

View full text Add to dashboard Cite

Viral mutations within patients nurture the adaptive potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during chronic infections, which are a potential source of variants of concern. However, there is no integrated framework for the evolutionary analysis of intra-patient SARS-CoV-2 serial samples. Herein, we describe Viral Intra-Patient Evolution Reporting and Analysis (VIPERA), a new software that integrates the evaluation of the intra-patient ancestry of SARS-CoV-2 sequences with the analysis of evolutionary trajectories of serial sequences from the same viral infection. We have validated it using positive and negative control datasets and have successfully applied it to a new case, which revealed population dynamics and evidence of adaptive evolution. VIPERA is available under a free software license at https://github.com/PathoGenOmics-Lab/VIPERA.

show abstract

Determining SARS-CoV-2 non-infectivity state–A brief overview

Brynjólfsson

Sigurgrimsdottir

Guðlaugsson

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

From the beginning of the COVID-19 pandemic, it has claimed over 6 million lives, and globally the pandemic rages with detrimental consequences, with the emergence of new more infectious and possibly virulent variants. A clinical obstacle in this battle has been to determine when an infected individual has reached a non-infectious state. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can be transmitted under diverse circumstances, and various rules and regulations, along with different testing methods, have been applied in an attempt to confine the transmission. However, that has proven to be a difficult task. In this review, we take together recently published data on infectivity and transmission of SARS-CoV-2 and have combined it with the clinical experience that physicians in Iceland have accumulated from the pandemic. In addition, we suggest guidelines for determining when patients with COVID-19 reach a non-infectious state based on a combination of clinical experience, scientific data, and proficient use of available tests. This review has addressed some of the questions regarding contagiousness and immunity against SARS-CoV-2.

show abstract

Highlight of potential impact of new viral genotypes of SARS-CoV-2 on vaccines and anti-viral therapeutics

Cited by 3 publications

References 67 publications

Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs

Network for network concept offers new insights into host- SARS-CoV-2 protein interactions and potential novel targets for developing antiviral drugs

VIPERA: Viral Intra-Patient Evolution Reporting and Analysis

Determining SARS-CoV-2 non-infectivity state–A brief overview

Contact Info

Product

Resources

About